WB007 / Whitecap Biosci - LARVOL DELTA

The Effect of BL1107 on Intraocular Pressure and Visual Function In a Phase 2 Randomized Clinical Trial in Patients with Glaucoma or Ocular Hypertension (ARVO 2026) - "Purpose A Phase 2 trial evaluated the safety and efficacy of BL1107 (formerly WB007), a potent, targeted alpha2 agonist in development to lower intraocular pressure (IOP) and acutely improve vision in patients with glaucoma. Methods 59 patients with glaucoma or ocular hypertension were enrolled in a 14-day randomized controlled trial comparing BL1107 (0.15% and 0.4%) to timolol (Tim) 0.5% each administered topically twice daily...BL1107 was well tolerated, with mostly mild and temporary side effects. These early results support further clinical testing of this promising new treatment."

Clinical • P2 data • Glaucoma • Ophthalmology

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2 | N=77 | Completed | Sponsor: Whitecap Biosciences, LLC | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2 | N=77 | Active, not recruiting | Sponsor: Whitecap Biosciences, LLC | Trial completion date: Dec 2021 ➔ Jan 2023

Trial completion date • Cardiovascular • Glaucoma • Ophthalmology

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2; N=77; Active, not recruiting; Sponsor: Whitecap Biosciences, LLC; Recruiting ➔ Active, not recruiting; Trial completion date: Jul 2021 ➔ Dec 2021

Clinical • Enrollment closed • Trial completion date • Glaucoma • Ophthalmology

Safety and IOP-Lowering Effects of WB007 (clinicaltrials.gov) - P1/2; N=100; Recruiting; Sponsor: Whitecap Biosciences, LLC; Trial completion date: Dec 2020 ➔ Jul 2021; Trial primary completion date: Jun 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Glaucoma • Hypertension • Ophthalmology

Newly added product (clinicaltrials.gov) - P2, Glaucoma

Pipeline update